Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Read more about Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women. Read more about Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women.
Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test. Read more about Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test.
Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Read more about Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
Combined effect of volumetric breast density and body mass index on breast cancer risk. Read more about Combined effect of volumetric breast density and body mass index on breast cancer risk.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Read more about Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Validation of the breast cancer surveillance consortium model of breast cancer risk. Read more about Validation of the breast cancer surveillance consortium model of breast cancer risk.
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Read more about The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Read more about Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Read more about A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
